WO2011038900A3 - Analogues peptidiques de glucagon pour une thérapie du diabète - Google Patents

Analogues peptidiques de glucagon pour une thérapie du diabète Download PDF

Info

Publication number
WO2011038900A3
WO2011038900A3 PCT/EP2010/005943 EP2010005943W WO2011038900A3 WO 2011038900 A3 WO2011038900 A3 WO 2011038900A3 EP 2010005943 W EP2010005943 W EP 2010005943W WO 2011038900 A3 WO2011038900 A3 WO 2011038900A3
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
glucagon
optionally
terminal
peptide analogues
Prior art date
Application number
PCT/EP2010/005943
Other languages
English (en)
Other versions
WO2011038900A2 (fr
Inventor
Finbarr Paul Mary O'harte
Original Assignee
University Of Ulster
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Ulster filed Critical University Of Ulster
Publication of WO2011038900A2 publication Critical patent/WO2011038900A2/fr
Publication of WO2011038900A3 publication Critical patent/WO2011038900A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un analogue peptidique de glucagon qui est à nouveau modifié par une ou plusieurs des modifications suivantes : (i) délétion d'au moins un acide aminé, facultativement choisi parmi His1 et Phe6 ; (ii) au moins une substitution d'un acide aminé L ou D pour l'acide aminé de type sauvage correspondant, facultativement à une ou plusieurs des positions 3, 4, 5, 6 et 9 ; (iii) modification C-terminale choisi parmi l'amidation de la Thr29 C-terminale ; (iv) la PEGylation de la Thr29 C-terminale ; et (v) l'addition d'un acide aminé L ou D, facultativement Lys, à la Thr29 C-terminale. L'invention concerne également des compositions pharmaceutiques contenant ces analogues et leurs utilisations dans des procédés de traitement du diabète.
PCT/EP2010/005943 2009-09-29 2010-09-29 Analogues peptidiques de glucagon pour une thérapie du diabète WO2011038900A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0917072.1 2009-09-29
GB0917072A GB0917072D0 (en) 2009-09-29 2009-09-29 Peptide analogues of glucagon for diabetes therapy

Publications (2)

Publication Number Publication Date
WO2011038900A2 WO2011038900A2 (fr) 2011-04-07
WO2011038900A3 true WO2011038900A3 (fr) 2011-06-23

Family

ID=41350545

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/005943 WO2011038900A2 (fr) 2009-09-29 2010-09-29 Analogues peptidiques de glucagon pour une thérapie du diabète

Country Status (2)

Country Link
GB (1) GB0917072D0 (fr)
WO (1) WO2011038900A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6352806B2 (ja) * 2011-09-23 2018-07-04 ノヴォ ノルディスク アー／エス 新規のグルカゴン類似体
GB201214493D0 (en) * 2012-08-14 2012-09-26 Univ Ulster Therapies
JP6594856B2 (ja) 2013-04-18 2019-10-23 ノヴォ ノルディスク アー／エス 医療用の安定な遷延性ｇｌｐ−１／グルカゴン受容体コアゴニスト
WO2015185640A1 (fr) 2014-06-04 2015-12-10 Novo Nordisk A/S Co-agonistes de récepteur du glucagon/glp-1 à usage médical
US20160151511A1 (en) 2014-12-02 2016-06-02 Antriabio, Inc. Proteins and protein conjugates with increased hydrophobicity
CA2972748A1 (fr) 2014-12-30 2016-07-07 Hanmi Pharm. Co., Ltd. Derive du glucagon a stabilite amelioree
JOP20200119A1 (ar) * 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
RU2730848C2 (ru) 2015-06-04 2020-08-26 Резолют, Инк. Способы пэгилирования по аминогруппе для получения сайт-специфичных конъюгатов белков
DK3322437T3 (da) 2015-06-30 2024-03-25 Hanmi Pharmaceutical Co Ltd Glukagonderivat og en sammensætning omfattende et langtidsvirkende konjugat af samme
EA038544B1 (ru) 2015-12-31 2021-09-13 Ханми Фарм. Ко., Лтд. Тройной агонист рецепторов глюкагона/glp-1/gip
IL263934B2 (en) 2016-06-29 2023-10-01 Hanmi Pharm Ind Co Ltd A derivative of glucagon, its conjugate, a preparation containing it and its medical use

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018153A1 (fr) * 1993-12-29 1995-07-06 The Rockefeller University Analogues du glucagon avec des remplacements de la serine en position 16 presentant une activite antagoniste
WO2001083527A2 (fr) * 2000-05-03 2001-11-08 Amgen Inc. Antagonistes de glucagon
WO2004111078A2 (fr) * 2003-06-18 2004-12-23 Theratechnologies Inc. Composes qui modulent la reponse du glucagon et utilisations associees
WO2009058734A1 (fr) * 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Composés présentant une activité d'antagoniste de glucagon et d'agoniste du glp-1
WO2009058662A2 (fr) * 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Antagonistes du glucagon

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
WO2004007524A2 (fr) 2002-07-17 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Oligopeptides bicycliques
AU2007323035B2 (en) 2006-10-03 2011-11-24 Cadila Healthcare Limited Antidiabetic compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018153A1 (fr) * 1993-12-29 1995-07-06 The Rockefeller University Analogues du glucagon avec des remplacements de la serine en position 16 presentant une activite antagoniste
WO2001083527A2 (fr) * 2000-05-03 2001-11-08 Amgen Inc. Antagonistes de glucagon
WO2004111078A2 (fr) * 2003-06-18 2004-12-23 Theratechnologies Inc. Composes qui modulent la reponse du glucagon et utilisations associees
WO2009058734A1 (fr) * 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Composés présentant une activité d'antagoniste de glucagon et d'agoniste du glp-1
WO2009058662A2 (fr) * 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Antagonistes du glucagon

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AHN J-M ET AL: "DEVELOPMENT OF POTENT GLUCAGON ANTAGONISTS: STRUCTURE-ACTIVITY RELATIONSHIP STUDY OF GLYCINE AT POSITION 4", JOURNAL OF PEPTIDE RESEARCH, BLACKWELL PUBLISHING LTD, OXFORD; GB, vol. 58, no. 2, 1 August 2001 (2001-08-01), pages 151 - 158, XP001039109, ISSN: 1397-002X, DOI: DOI:10.1034/J.1399-3011.2001.00880.X *
CHRISTOPHE J: "Glucagon receptors: From genetic structure and expression to effector coupling and biological responses", BIOCHIMICA ET BIOPHYSICA ACTA - REVIEWS ON BIOMEMBRANES 1995 NL LNKD- DOI:10.1016/0304-4157(94)00015-6, vol. 1241, no. 1, 1995, pages 45 - 57, XP002632309, ISSN: 0304-4157 *
RAMALINGA DHARANIPRAGADA: "SYNTHETIC LINEAR AND CYCLIC GLUCAGON ANTAGONISTS", INTERNATIONAL JOURNAL OF PEPTIDE AND PROTEIN RESEARCH, MUNKSGAARD, COPENHAGEN, DK, vol. 42, no. 1, 1 July 1993 (1993-07-01), pages 68 - 77, XP000372575, ISSN: 0367-8377 *

Also Published As

Publication number Publication date
WO2011038900A2 (fr) 2011-04-07
GB0917072D0 (en) 2009-11-11

Similar Documents

Publication Publication Date Title
WO2011038900A3 (fr) Analogues peptidiques de glucagon pour une thérapie du diabète
MX2008009493A (es) Peptido novedoso y uso del mismo.
NZ621196A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
IL199263A (en) Glucagon peptide with enhanced solubility, pharmaceutical composition containing it and its uses for drug preparation
NZ628987A (en) Extended recombinant polypeptides and compositions comprising same
NZ599161A (en) Method for activation of helper t cell and composition for use in the method
RU2011134596A (ru) Аналоги оксинтомодулина
UA103154C2 (uk) Hla-a*1101-обмежений пептид wt1 і фармацевтична композиція, яка містить його
PE20121393A1 (es) Analogo peptidico de oxintomodulina
MY149527A (en) Hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same
RU2017119773A (ru) Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение
MX2009004701A (es) Analogos selectivos del peptido 2 similar al glucagon.
PE20090108A1 (es) Coagonistas del receptor de glucagon/glp-1
EA019203B9 (ru) Коагонисты глюкагонового рецептора/glp-1-рецептора
MX2010004297A (es) Antagonistas de glucagon.
MX2010012695A (es) Analogos de glucagon que exhiben solubilidad y estabilidad aumentadas en soluciones reguladoras de ph fisiologico.
HK1088840A1 (en) Stable analogs of glp-1 glp-1
JP2013543497A5 (fr)
WO2010085700A3 (fr) Traitement de l'obésité
WO2008075371A3 (fr) Analogues peptidiques de t-140 présentant une activité superagoniste par rapport à cxcr4 destinés à une immunomodulation
NZ708990A (en) Method for activating helper t cell
MX353301B (es) Composiciones tripeptidicas y metodos para tratamiento de diabetes.
NZ614557A (en) Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
EP3026057A3 (fr) Compositions pour la prévention et le traitement de maladies neurodégénératives
WO2008114577A2 (fr) Peptide antibactérien

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10765577

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10765577

Country of ref document: EP

Kind code of ref document: A2